A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-Cell and Peripheral T-Cell Non-Hodgkin Lymphoma
Phase of Trial: Phase II
Latest Information Update: 11 May 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 01 May 2017 Planned End Date changed from 1 Aug 2025 to 1 Aug 2019.
- 01 May 2017 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
- 13 Dec 2012 New source identified and integated (M.D. Anderson Cancer Center; 2011-0856).